Clinical Trial

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2024 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Traditional treatment regimens mainly include chemotherapy and hematopoietic stem cell transplantation. In the past decade, with the application of molecular targeted drugs and immunotherapy, the survival of B-ALL patients has significantly improved. In this study，we propose a treatment approach that combines Blinatumomab and Venetoclax sequenced with Inotuzumab Ozogamicin in B-ALL adults. Our study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.
Trial Details
NCT Number NCT06554626
Lead Sponsor First Affiliated Hospital of Zhejiang University
Conditions Precursor B-Cell Lymphoblastic Leukemia
Enrollment 20 participants
Start Date 2024-08-15
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-15